We are live on ! Find out more
CNSP icon

CNS Pharmaceuticals
CNSP

5 hedge funds and large institutions have $234K invested in CNS Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 5 funds opening new positions, increasing their positions, reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more funds holding

Funds holding: 2 → 5 (+3)

150% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 2

23% more capital invested

Capital invested by funds: $190K → $234K (+$44K)

0% less ownership

Funds ownership: 0% → 0% (-0%)

Holders
5
Holders Change
+3
Holders Change %
+150%
% of All Funds
0.08%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
–
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$53.7K
2
FWA
FSM Wealth Advisors
Ohio
+$53.7K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$53.7K
4
State Street
State Street
Massachusetts
+$53.7K
5
Vanguard Group
Vanguard Group
Pennsylvania
+$53.7K

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$124K
2
Renaissance Technologies
Renaissance Technologies
New York
-$27K
3
Citadel Advisors
Citadel Advisors
Florida
-$13.2K
4
VF
Virtu Financial
New York
-$11K
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$200
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$53K +$53.7K +1 New
State Street
2
State Street
Massachusetts
$50.3K +$53.7K +1 New
Acadian Asset Management
3
Acadian Asset Management
Massachusetts
$49K +$53.7K +1 New
FWA
4
FSM Wealth Advisors
Ohio
$37.9K +$53.7K +1 New
Geode Capital Management
5
Geode Capital Management
Massachusetts
$36K +$53.7K +1 New
TRCT
6
Tower Research Capital (TRC)
New York
$4.4K – – –
UBS Group
7
UBS Group
Switzerland
$2.51K – – –
Wells Fargo
8
Wells Fargo
California
$1.12K – – –
GRP
9
Global Retirement Partners
California
$118 – – –
Osaic Holdings
10
Osaic Holdings
Arizona
$94 – – –
Bank of America
11
Bank of America
North Carolina
$15 – – –
PMFA
12
Plante Moran Financial Advisors
Michigan
$2 – – –
AC
13
Armistice Capital
New York
– -$124K -4 Closed
Renaissance Technologies
14
Renaissance Technologies
New York
– -$27K -1 Closed
Citadel Advisors
15
Citadel Advisors
Florida
– -$13.2K – –
Fidelity Investments
16
Fidelity Investments
Massachusetts
– -$200 – –
GI
17
Gradient Investments
Minnesota
– -$7 – –
VF
18
Virtu Financial
New York
– -$11K – –

CNSP Hedge Fund Activity: Q2 2023 in Review

5 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in CNS Pharmaceuticals (CNSP) for Q2 2023, worth a combined $234K — up 23% from $190K a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new CNSP positions and 2 closed out — a net gain of 3 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Acadian Asset Management, opening a new position worth an estimated $53.7K. The largest seller was Armistice Capital, exiting entirely with an estimated $124K sold.

  • 5 institutional investors held CNS Pharmaceuticals (CNSP) as of Q2 2023, up from 2 in Q1 2023.
  • Funds reported $234K of CNS Pharmaceuticals stock for Q2 2023, up 23% quarter-over-quarter.
  • 5 funds opened new CNS Pharmaceuticals positions in Q2 2023 and 2 closed out, a net change of +3 holders.
  • The largest CNS Pharmaceuticals buyer in Q2 2023 was Acadian Asset Management, an estimated $53.7K added.
  • The largest CNS Pharmaceuticals seller in Q2 2023 was Armistice Capital, an estimated $124K sold.

Based on aggregated 13F filings for Q2 2023.